Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bio-Rad Laboratories, Inc. (BIO.B : NYSE)
 
 • Company Description   
BIO-RAD LABORATORIES, INC. manufactures and supplies to life sciences research, healthcare, analytical chemistry, semiconductor and other markets a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $505.00 Daily Weekly Monthly
20 Day Moving Average: 193 shares
Shares Outstanding: 29.94 (millions)
Market Capitalization: $15,120.51 (millions)
Beta: 0.78
52 Week High: $818.60
52 Week Low: $504.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.53% 0.23%
12 Week -20.96% -14.24%
Year To Date -30.14% -16.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1000 ALFRED NOBEL DR
-
HERCULES,CA -
USA		 ph: 510-724-7000
fax: 1-510-7415815		 investor_relations@bio-rad.com http://www.bio-rad.com
 
 • General Corporate Information   
Officers
Norman Schwartz - Chief Executive Officer and Chairman
Norman Schwartz - President and Director
Ilan Daskal - Senior Vice President and Chief Accounting Officer
Christine A. Tsingos - Vice President;Chief Financial Officer
Ajit Ramalingam - Senior Vice President and Chief Accounting Officer

Peer Information
Bio-Rad Laboratories, Inc. (CORR.)
Bio-Rad Laboratories, Inc. (RSPI)
Bio-Rad Laboratories, Inc. (CGXP)
Bio-Rad Laboratories, Inc. (BGEN)
Bio-Rad Laboratories, Inc. (GTBP)
Bio-Rad Laboratories, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 090572108
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 29.94
Most Recent Split Date: 3.00 (2.00:1)
Beta: 0.78
Market Capitalization: $15,120.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 32.79
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: 31.94
Price / Sales: 5.22
EPS Growth
vs. Year Ago Period: -5.18%
vs. Previous Quarter: 53.89%
Sales Growth
vs. Year Ago Period: -3.68%
vs. Previous Quarter: -4.46%
ROE
03/31/22 - 3.66
12/31/21 - 3.70
09/30/21 - 4.19
ROA
03/31/22 - 2.77
12/31/21 - 2.83
09/30/21 - 3.21
Current Ratio
03/31/22 - 5.10
12/31/21 - 2.92
09/30/21 - 3.79
Quick Ratio
03/31/22 - 4.16
12/31/21 - 2.08
09/30/21 - 2.89
Operating Margin
03/31/22 - 16.06
12/31/21 - 16.19
09/30/21 - 16.69
Net Margin
03/31/22 - -3.49
12/31/21 - 145.28
09/30/21 - 223.47
Pre-Tax Margin
03/31/22 - -7.95
12/31/21 - 186.08
09/30/21 - 287.11
Book Value
03/31/22 - 340.09
12/31/21 - 456.60
09/30/21 - 512.48
Inventory Turnover
03/31/22 - 2.12
12/31/21 - 2.17
09/30/21 - 2.12
Debt-to-Equity
03/31/22 - 0.12
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 10.52
12/31/21 - 0.08
09/30/21 - 0.07
 

Powered by Zacks Investment Research ©